Assessing the TP53 marker type in patients treated with or without neoadjuvant chemotherapy for resectable colorectal liver metastases: a p53 Research Group study

European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
N PilatD Kandioler

Abstract

The type of a biomarker - whether it is prognostic or predictive - is frequently not known, although such information is crucial for assessing the clinical value of a marker. In order to evaluate the type of marker TP53 is, we identified a cohort of 76 patients with colorectal liver metastases (CLM), homogeneously staged as resectable, who had been treated either with or without fluorouracil-based neoadjuvant chemotherapy. The TP53 genotype was assessed retrospectively from paraffin-embedded, diagnostic tumour biopsies using a standardised, p53 gene-specific sequencing protocol (mark53(®) kit). The overall median survival was 44.2 months, and the overall TP53 mutation frequency was 55%. A significant interaction was observed between chemotherapy and TP53 status (P = 0.045). To illustrate this effect, the 51 patients with and the 25 patients without neoadjuvant chemotherapy were described separately. In patients with neoadjuvant chemotherapy, mutated TP53 was significantly associated with poor survival (P = 0.0025), resulting in five-year survival rates of 22%, compared to 60% in patients with normal TP53. The hazard ratio was 3.12 (95% confidence intervals (CI): 1.46-6.95) to the disadvantage of TP53-mutated patients and 5.49 (...Continue Reading

References

Apr 6, 2001·Diseases of the Colon and Rectum·S PetersenM Baumann
Mar 21, 2002·Nature Reviews. Cancer·T Soussi, C Béroud
Jun 27, 2003·Proceedings of the National Academy of Sciences of the United States of America·Shunsuke KatoChikashi Ishioka
Jan 8, 2005·Clinical Chemistry·Michael J Duffy
Mar 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel J SargentLaurence Collette
Sep 21, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio RussoUNKNOWN TP53-CRC Collaborative Study Group
Sep 28, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paulo M Hoff
Apr 1, 2006·Cancer Biology & Therapy·Scott E Kern, Jordan M Winter
Jul 28, 2006·Cold Spring Harbor Symposia on Quantitative Biology·D P Lane
Aug 26, 2006·Breast Cancer Research and Treatment·Lisa M McShaneUNKNOWN Statistics Subcommittee of NCI-EORTC Working Group on Cancer Diagnostics
May 22, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M J DuffyO Topolcan
May 6, 2008·The Journal of Thoracic and Cardiovascular Surgery·Daniela KandiolerWalter Klepetko
Nov 21, 2008·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Laia AgellJosep Lloreta
Jul 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sumithra J Mandrekar, Daniel J Sargent
Sep 5, 2009·Nature Reviews. Cancer·David W Meek
Apr 16, 2010·Clinical Trials : Journal of the Society for Clinical Trials·Sumithra J Mandrekar, Daniel J Sargent
May 26, 2012·Proceedings of the National Academy of Sciences of the United States of America·Karolina EdlundThierry Soussi
Oct 1, 2014·Annals of the New York Academy of Sciences·Junichi AkiyamaBrigitte Wolf

❮ Previous
Next ❯

Citations

Oct 2, 2015·EBioMedicine·Daniela KandiolerUNKNOWN p53 Research Group and the Austrian Breast and Colorectal Study Group (ABCSG)
Dec 6, 2016·Acta Clinica Belgica·Pieter-Jan Cuyle, Hans Prenen
Apr 13, 2018·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·Carlotta BarbonMatthew J Weiss
Aug 17, 2018·Annals of the New York Academy of Sciences·Tamara BraunschmidDaniela Kandioler
Oct 5, 2018·International Journal of Molecular Sciences·Gianluca LopezAlessandro Del Gobbo
Dec 19, 2018·European Surgery : ACA : Acta Chirurgica Austriaca·Sonja Kappel-LatifUNKNOWN Pancho trialists and for the Medical University of Vienna p53research group
Jul 30, 2021·World Journal of Gastrointestinal Oncology·Hande BeklenKazim Yalcin Arga

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.